Stanford-StartX Fund-backed microbial diagnostics and wellness product developer UBiome has raised $83m in series C funding.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.

The MIT-affiliated Engine Fund has achieved a final close of more than $205m, above its initial target of $150m.

Duke University’s OLV managed a near-50% increase on 2017’s spinout tally in a year where its businesses generated $526m in capital.

David Broecker has become PRF’s chief innovation and collaboration officer, bringing with him expertise from the biosciences and philanthropic funding agency IBRI.

Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.

Nationwide Children’s Hospital spinout Celenex could fetch as much as $452m upon completion of milestones after progressing rare disease therapies conceived at the hospital’s collaborative program with Ohio State University.

Organic snack producer SMPL has been backed by Zell Founders Fund, a VC vehicle run by University of Michigan students.

The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

US-based website creation tool developer Strikingly has received more than $10m in a series A-plus round that featured CAS Holding.